366 related articles for article (PubMed ID: 27109805)
1. Effect of tiotropium on COPD exacerbations: A systematic review.
Halpin DM; Vogelmeier C; Pieper MP; Metzdorf N; Richard F; Anzueto A
Respir Med; 2016 May; 114():1-8. PubMed ID: 27109805
[TBL] [Abstract][Full Text] [Related]
2. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
Halpin DM; Kaplan AG; Russell RK
Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
[TBL] [Abstract][Full Text] [Related]
3. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
4. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
5. Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.
Jones PW
Ther Adv Respir Dis; 2015 Jun; 9(3):84-96. PubMed ID: 25801643
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
7. Inhaled tiotropium for stable chronic obstructive pulmonary disease.
Barr RG; Bourbeau J; Camargo CA; Ram FS
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002876. PubMed ID: 15846642
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Chapman KR; Hurst JR; Frent SM; Larbig M; Fogel R; Guerin T; Banerji D; Patalano F; Goyal P; Pfister P; Kostikas K; Wedzicha JA
Am J Respir Crit Care Med; 2018 Aug; 198(3):329-339. PubMed ID: 29779416
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.
Keating GM
Drugs; 2012 Jan; 72(2):273-300. PubMed ID: 22217233
[TBL] [Abstract][Full Text] [Related]
10. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Ulrik CS
Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development.
Anzueto A; Miravitlles M
Respir Res; 2020 Jul; 21(1):199. PubMed ID: 32727455
[TBL] [Abstract][Full Text] [Related]
13. Ten years of tiotropium: clinical impact and patient perspectives.
Yohannes AM; Connolly MJ; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2013; 8():117-25. PubMed ID: 23515335
[TBL] [Abstract][Full Text] [Related]
14. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
[TBL] [Abstract][Full Text] [Related]
16. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Ficker JH; Rabe KF; Welte T
Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.
Tricco AC; Strifler L; Veroniki AA; Yazdi F; Khan PA; Scott A; Ng C; Antony J; Mrklas K; D'Souza J; Cardoso R; Straus SE
BMJ Open; 2015 Oct; 5(10):e009183. PubMed ID: 26503392
[TBL] [Abstract][Full Text] [Related]
18. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.
D'Urzo A; Bader G; Shen S; Goyal P; Altman P
NPJ Prim Care Respir Med; 2018 May; 28(1):18. PubMed ID: 29795478
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]